Table 2 Pooled results of the meta-analysis of the diagnostic accuracy of CTCs detection in gastric cancer
Analysis scenario | Sensitivity | Specificity | Positive LR | Negative LR | DOR | Heterogeneity* |
|---|---|---|---|---|---|---|
All studies | 0.42 (0.21, 0.67) | 0.99 (0.96, 1.00) | 58.2 ( 9.8, 345.9) | 0.58 (0.38, 0.89) | 100 (15, 663) | 98 (98, 99) |
All studies without outliers | 0.37 (0.16, 0.65) | 0.99 (0.96, 1.00) | 65.4 (8.4, 511.4) | 0.63 (0.42, 0.96) | 104 (11, 956) | 94 (89, 99) |
Subgroup: CEA | 0.31 (0.10, 0.64) | 0.94 (0.87, 0.98) | 5.4 (2.1, 14.0) | 0.73 (0.49, 1.09) | 7 ( 2, 26) | 98 (96, 99) |
Subgroup: CK-19 | 0.27 (0.06, 0.67) | 0.95 (0.90, 0.98) | 5.4 (1.7, 16.4) | 0.77 (0.50, 1.19) | 7 (2, 31) | 97 (96, 99) |
Subgroup: CK-20 | 0.25 (0.13, 0.43) | 0.95 (0.89, 0.98) | 4.9 (1.6, 14.9) | 0.79 (0.64, 0.98) | 6 (2, 23) | 0 (0, 100) |
Subgroup: stage 1 | 0.22 (0.06, 0.56) | 0.95 (0.89, 0.98) | 4.3 (1.1, 17.7) | 0.82 (0.59, 1.15) | 5 (1, 29) | 91 (83, 100) |
Subgroup: stage 2 | 0.40 (0.14, 0.73) | 0.96 (0.90, 0.98) | 9.7 (4.5, 20.9) | 0.62 (0.37, 1.07) | 15 (5, 48) | 93 (86, 99) |
Subgroup: stage 3 | 0.46 (0.16, 0.80) | 0.95 (0.90, 0.98) | 9.4 (3.4, 25.9) | 0.56 (0.28, 1.15) | 17 (3, 83) | 94 (89, 99) |
Subgroup: stage 4 | 0.63 (0.43, 0.79) | 0.97 (0.95, 0.98) | 20.6 (11.2, 38.0) | 0.38 (0.23, 0.64) | 54 (21, 138) | 71 (35,100) |
Subgroup: stage 1-3 | 0.30 (0.09, 0.64) | 0.96 (0.91, 0.98) | 6.9 (2.2,21.3) | 0.73 (0.48, 1.12) | 9 (2, 42) | 97 (95, 99) |
Subgroup: PCR-based assay | 0.39 (0.20, 0.60) | 0.94 (0.90, 0.96) | 6.1 (3.6, 10.4) | 0.94 (0.90, 0.96) | 9 (4, 21) | 96 (95, 97) |
Subgroup: immunological assay | 0.82 (0.43, 1.00) | 1.00 (0.98, 1.00) | 74.5 (15.0,368.9) | 0.335 (0.12-0.97) | 340.9 (23.26,4996.7) | 93 (88, 97) |